Rare Wolf Capital LLC Invests $3.56 Million in Pfizer Inc. $PFE

Rare Wolf Capital LLC purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 142,780 shares of the biopharmaceutical company’s stock, valued at approximately $3,555,000. Pfizer comprises approximately 2.2% of Rare Wolf Capital LLC’s portfolio, making the stock its 7th largest holding.

Several other large investors have also recently modified their holdings of PFE. Kepler Cheuvreux Suisse SA bought a new position in Pfizer during the third quarter valued at approximately $16,613,000. Mackenzie Financial Corp grew its position in Pfizer by 119.6% in the 3rd quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock worth $79,157,000 after purchasing an additional 1,691,773 shares during the period. Penn Davis Mcfarland Inc. grew its position in Pfizer by 50.9% in the 4th quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock worth $4,266,000 after purchasing an additional 57,777 shares during the period. Pzena Investment Management LLC raised its stake in Pfizer by 0.9% during the 3rd quarter. Pzena Investment Management LLC now owns 6,615,598 shares of the biopharmaceutical company’s stock valued at $168,565,000 after buying an additional 56,484 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its holdings in shares of Pfizer by 48.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock valued at $468,174,000 after buying an additional 5,978,927 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Negative Sentiment: Pfizer announced that Chief Financial Officer Dave Denton will step down on August 15 for an external opportunity, prompting concerns about leadership continuity and execution at a time when investors are closely watching the company’s 2026 outlook. Reuters article
• Negative Sentiment: The market appears to be treating the CFO transition as a near-term uncertainty, with several reports noting that Pfizer’s shares fell as investors reassessed growth catalysts and financial stability. TipRanks article
• Neutral Sentiment: Pfizer named Cecile Guegan as interim CFO and said it is conducting a comprehensive search for a permanent replacement, which helps reduce uncertainty but does not fully remove investor concerns. Business Wire article
• Neutral Sentiment: The company reaffirmed its full-year 2026 guidance, which should limit downside if management can maintain operational momentum despite the executive transition. TipRanks article
• Positive Sentiment: Recent business updates, including progress on the obesity pipeline and a China partnership expansion, provide longer-term growth optionality, though they were not enough to offset today’s leadership-driven selloff. Yahoo Finance article

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on PFE shares. CICC Research began coverage on Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target on the stock. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Guggenheim increased their target price on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Citigroup raised their target price on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Finally, HSBC boosted their price target on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.82.

Pfizer Trading Down 2.6%

Shares of Pfizer stock opened at $25.25 on Friday. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75. The company’s fifty day simple moving average is $26.26 and its 200-day simple moving average is $26.33. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The stock has a market capitalization of $143.94 billion, a PE ratio of 19.28 and a beta of 0.34.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Stockholders of record on Friday, May 8th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.